Keyphrases
Adverse Event Rates
11%
Adverse Events
11%
Antineoplastic Drugs
11%
Arms Control
11%
Bevacizumab
33%
Blood-brain Barrier
33%
Blood-brain Barrier Permeability
11%
Brain Tumor
11%
Cox Proportional Hazards Model
11%
Doxorubicin
100%
Doxorubicin Treatments
11%
Drug Delivery
11%
Historical Controls
44%
IDH mutation
11%
Local Recurrence-free Survival
11%
MGMT Promoter
11%
No Significant Difference
11%
Overall Survival
44%
Peritumoral
11%
Phase II Study
100%
Photothermal Therapy
100%
Progression Pattern
11%
Progression-free Survival
33%
Recurrent Glioblastoma
100%
Salvage Chemotherapy
11%
Salvage Therapy
33%
Survival Trends
11%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
40%
Anticarcinogen
20%
Bevacizumab
60%
Blood-Brain Barrier
80%
Chemotherapy
20%
Doxorubicin
100%
Glioblastoma
100%
Intracranial Tumor
20%
Overall Survival
80%
Progression Free Survival
80%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
60%
Blood Brain Barrier
80%
Doxorubicin
100%
Low Drug Dose
60%
Overall Survival
80%
Progression Free Survival
80%
Promoter Region
20%
Neuroscience
Anticarcinogen
20%
Antineoplastic Drugs
20%
Bevacizumab
60%
Blood Brain Barrier
80%
Doxorubicin
100%
Intracranial Tumor
20%
Promoter Region
20%